HC Wainwright & Co. Reiterates Buy on MapLight Therapeutics, Maintains $45 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 91.0%

Neg 0% Neu 91% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MapLight Therapeutics (NASDAQ:MPLT) with a Buy and maintains $45 price target.